Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis

Seungwon Yang*, Siyoung Yang*, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon and Yun Mi Yu

Abstract

Background: A large proportion of patients with inflammatory bowel disease (IBD) relapse after drug discontinuation despite achieving a stable state of infliximab-induced clinical remission. Resuming the use of the same tumor necrosis factor-alpha (TNF-α) inhibitors in patients who relapse following TNF-α inhibitor discontinuation was suggested as a treatment strategy. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of infliximab retreatment in patients with IBD.

Methods: A systematic literature search to shortlist relevant studies was conducted using the MEDLINE, Embase, CINAHL, and SCOPUS databases for studies published from inception to August 2020.

Results: Nine studies were included in the meta-analysis. The pooled clinical remission rate of infliximab retreatment in patients with IBD was 85% (95% confidence interval (CI), 81–89%) for induction treatment and 73% (95% CI, 66–80%) for maintenance treatment. A clinical remission rate following infliximab reintroduction was achieved in a greater proportion of patients with Crohn’s disease (87%; 95% CI, 83–91%) than in those with ulcerative colitis (78%; 95% CI, 61–91%) for induction treatment, but the difference was not statistically significant. Infusion-related reactions after infliximab retreatment occurred in 9% of patients with IBD (95% CI, 3–16%).

Conclusion: Infliximab retreatment showed high clinical remission rates with tolerable infusion-related reactions in patients with IBD who achieved remission with initial infliximab treatment but relapsed after its discontinuation. We suggest infliximab as a viable alternative in patients with IBD who previously responded well to infliximab treatment.

Keywords: clinical remission, inflammatory bowel disease, infliximab, infusion-related reaction, retreatment

Received: 22 March 2021; revised manuscript accepted: 3 August 2021.

Introduction

Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic immune-mediated diseases characterized by uncontrolled inflammation of the gastrointestinal tract.1,2 Therapeutic strategies for the management of IBD include conventional therapies with 5-aminosalicylic acid drugs, corticosteroids, and immunomodulators and biologic therapy with tumor necrosis factor-alpha (TNF-α) inhibitors.3,4 Infliximab, a chimeric monoclonal IgG1 antibody against TNF-α, is one of the preferred treatment options among TNF-α inhibitors5,6 and has proven to be efficacious as induction and
maintenance therapy for patients with refractory IBD.7,8 Despite the success of infliximab for achieving remission and improving clinical outcomes, approximately half of patients with IBD who have achieved clinical remission relapse within 1 year after its discontinuation due to patient preference, cost, or potential for adverse effect, and so on.9 European Crohn’s and Colitis Organization suggested resuming the use of the same TNF-α inhibitors in patients who relapse following TNF-α inhibitor discontinuation as an ‘exit strategy’.10

Retreatment with infliximab can be considered an alternative for patients with IBD who relapse after discontinuation. However, conflicting results regarding clinical outcomes have been reported after infliximab retreatment,11,12 including the development of antibodies against infliximab, increased risk of severe systemic reactions, and shortened duration of efficacy, which limit its usefulness.13,14 Kugathasan et al12 reported that infliximab retreatment is associated with high rates of severe systemic reactions in adults and should only be used in safe, well-controlled clinical settings. In contrast, a multicenter study demonstrated clinical remission in 79% of patients with IBD,11 with adverse events in only 13% of patients following infliximab reinduction, suggesting that infliximab can be safely and effectively reintroduced.15 Therefore, it remains unclear whether infliximab retreatment is effective and tolerable in patients with IBD who relapsed after its discontinuation. As prospective randomized comparative studies on infliximab retreatment are difficult to conduct due to ethical issues, including those associated with deliberate drug suspension and resumption, it is preferable to collect data from reported studies and investigate its effects using a meta-analysis.

Therefore, in this study, we conducted a meta-analysis and systematic review to evaluate the efficacy and safety of infliximab retreatment in patients with IBD who initially responded to infliximab but relapsed after its discontinuation.

Materials and methods
This study followed the guidelines recommended by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) (Supplementary Table 1).16

Search strategy
The MEDLINE, Embase, CINAHL, and SCOPUS electronic databases were systematically searched for relevant studies published from inception to 15 August 2020. A comprehensive literature search was conducted using a combination of the following keywords and medical subject headings: ‘inflammatory bowel disease’, ‘Crohn’s disease’, ‘colitis, ulcerative’, ‘infliximab’, ‘re-treatment’, and ‘reinduction’. The detailed search strategies for each electronic database used in this analysis are provided in Supplementary Table 2. Our search was not restricted to any language.

Study selection
Two authors (S.Y. and Y.K.J.) independently conducted the literature search and followed the study selection protocol. Discrepancies were resolved by consensus. Studies were considered eligible if they met the following inclusion criteria: (1) population: patients diagnosed with IBD; (2) intervention: patients who restarted infliximab treatment after discontinuation of initial infliximab treatment for an interval and had no history of any other biologic therapy; (3) outcome: the proportion of patients who experienced either induction of remission, maintenance of remission, or infusion-related reactions. In this review, remission includes clinical, biochemical, or endoscopic remission defined as a state with completely symptom-free or steroid-free remission, pediatric Crohn’s Disease Activity Index ≤ 10, Crohn’s Disease Activity Index score of <150, partial Mayo score of ≤3, C-reactive protein <10 mg/l, or closure of all fistulas based on endoscopic or magnetic resonance examination;17 and (4) study design: prospective or retrospective controlled or uncontrolled studies excluding case reports. Studies were excluded if they were (1) nonhuman studies, including animal and in vitro studies; (2) available only in the form of abstracts or posters; and (3) reviews, meta-analyses, letters, editorials, or ongoing studies.

Data extraction
The eligible studies were reviewed, and the following data were extracted using a standardized extraction form: first author, publication year, country, study design, number of patients, sex,
age, infliximab drug holiday, infliximab retreatment regimen, concomitant medications, follow-up period, definition of clinical outcomes, rates of remission induction at 3 months after infliximab reinitiation, and maintained rates of remission after remission induction, which were assessed 1 year after infliximab reinitiation, incidence of infusion-related reactions, proportion of patients who tested positive for anti-infliximab antibodies, and serum concentration of infliximab.

**Assessment of risk of bias**

The risk of bias of the included studies was evaluated using a modified Methodological Index for Non-Randomized Study (MINORS),\(^1\) which contains the following eight items designed specifically for noncomparative studies: (1) clearly stated aim, (2) inclusion of consecutive patients, (3) prospective data collection, (4) endpoints appropriate according to study aim, (5) unbiased assessment of the study endpoints, (6) follow-up period appropriate to study aim, (7) <5% loss of patients during follow-up, and (8) prospective calculation of study size. The items were scored as 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The scores were evaluated as: 0–4, very low quality; 5–8, low quality; 9–12, moderate quality; and 13–16, high quality.\(^1\) Two authors independently assessed the potential degree of bias, and any disagreement between the authors was resolved by consensus.

**Statistical analysis**

The efficacy outcomes were the rates of induction of remission at 3 months after infliximab reintroduction and subsequent maintenance of remission at 1 year, which were presented as ‘induction of remission’ and ‘maintenance of remission’, respectively, and the safety outcome was the proportion of patients who experienced any infliximab-related infusion reaction after its reintroduction. The pooled estimates of rates for induction remission, maintenance remission, and infliximab-related infusion reactions were calculated using meta-analyses. Heterogeneity among studies was detected using inconsistency statistics ($I^2$).\(^2\) A random-effects model was used when potential heterogeneity existed ($I^2 > 40\%$); otherwise, a fixed-effects model was employed.\(^3\)

Moreover, the restricted maximum likelihood method was used to estimate the parameters of a random coefficient model, and the value of tau-squared ($\tau^2$) was used to estimate between-study variance.\(^4\)

Subgroup and sensitivity analyses were performed to remove heterogeneity and evaluate treatment effects based on the subgroup of patients with different diagnoses and study design. To investigate whether treatment efficacy was reduced according to the duration of infliximab discontinuation, the remission rate was stratified according to the studies in which the minimum duration of infliximab discontinuation was reported as $>$16 weeks. Moreover, a meta-regression was performed to investigate the association of remission rate and the incidence of infusion-related reactions with the proportion of concomitant immunomodulators. Statistical significance was defined as $p < 0.05$. The metaprop module in the R, version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria) statistical software package and the Comprehensive Meta-analysis, version 2 (Biostat, Englewood, NJ, USA) were used for analysis.

**Results**

The results of the study selection process are shown in Figure 1. We initially identified 459 articles through an electronic database search. After removing duplicates, 246 articles were screened for relevance based on the title and abstract, resulting in the exclusion of 199 articles that did not include patients with IBD, infliximab retreatment, or efficacy or safety outcomes of infliximab or were review, comments, or conference abstracts. Next, 47 relevant articles were assessed for eligibility through full-text evaluation. Finally, nine studies were selected for meta-analysis: five studies involving patients with CD, one involving patients with UC, and three involving both patients with CD and UC.\(^4\) Among the nine studies, eight studies, excluding a study by Rodrigo et al., evaluated the remission rate of infliximab retreatment, and seven studies, excluding the studies by Laharie et al. and Dai et al., evaluated the incidence of infusion-related reactions after infliximab retreatment.

Table 1 summarizes the characteristics of the included studies. In total, 428 patients, who...
reinitiated infliximab treatment after discontinuation for a reported median duration of 4–26.7 months, were included in this meta-analysis. Most studies were conducted in Europe, and the remaining two studies by Kang et al. and Dai et al. were conducted in Asia. All retrieved studies were nonrandomized, single-arm, observational studies, five of which were retrospective and four were prospective. Participants in the included studies received an intravenous dose of 5 mg/kg, except for a small proportion (<3%) of participants in one study who were administered an intravenous dose of either 7.5 or 10 mg/kg at 0, 2, and 6 weeks.26

The proportion of patients who received concomitant immunomodulator therapy during infliximab discontinuation and retreatment, ranged from 61% to 100%, as reported in five studies (Table 1). The proportion of patients who were antibody-positive for infliximab was measured at cessation and after the initiation of retreatment in three studies (Table 1). However, the detectable level of antibody positivity for infliximab was not consistent among the studies. The proportion of antibody-positive patients for infliximab after the initiation of retreatment was 40% with a cut-off of 3 U/ml in the study by Baert et al.; although the proportion of patients who were antibody-negative for infliximab was 27% in the study by Louice et al., data for the remaining 73% were inconclusive due to the interference of circulating infliximab with level >1 mg/ml. The median serum concentrations (interquartile range) of infliximab reported in the studies by Louis et al. and Baert et al. were 3.7 (1.7–8.0) µg/ml and 5.2 (0.36–17.3) µg/ml, respectively.

Clinical remission

Eight studies involving 358 patients reported clinical remission rates following infliximab retreatment in patients with IBD. The pooled remission rate after infliximab retreatment was 85% (95% confidence interval (CI), 81–89%; \( P = 5\); \( \tau^2 = 0.003, p = 0.39 \)) for induction treatment (at least 3 months) and 73% (95% CI, 66–80%; \( P = 30\); \( \tau^2 = 0.003, p = 0.23 \)) for maintenance treatment (at least 1 year) (Figure 2). The heterogeneity was low. Upon further subanalysis of induction treatment, a higher remission rate following infliximab reinduction was observed in patients with CD (87%; 95% CI, 83–91%; \( P = 4\); \( \tau^2 = 0.003, p = 0.40 \)) than in those

---

**Figure 1.** Flow chart of the study selection process.
Table 1. Characteristics of studies included in the meta-analysis.

| Study          | Study design/country                  | Number of patients | Sex (M/F) | Age, years (median, IQR) | Discontinuation interval, months (median, range) | IFX retreatment regimen | Concomitant use of IMM, n (%) | Follow-up period, years (median, range) | Definition of remission                                                                 | Proportion of anti-IFX-positive patients (%) |
|----------------|---------------------------------------|--------------------|-----------|--------------------------|-------------------------------------------------|-------------------------|-------------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------|
| Kang et al.    | Single-center, retrospective study/Korea| 33                 | 47/16     | 14.9c                    | 3 (at least)                                    | 5 mg/kg IV induction [W 0, 2, and 6]               |                               | 4.3n                                   | PCDAI < 10 CRP < 0.5 mg/dL              | 4.1n                                                                                           |
| Baert et al.   | Single-center, retrospective study/Belgium| 128                | 57/71     | 33.5c                    | 15 (6–125)                                      | 5 mg/kg IV induction [W 0, 2, and 6] or single infusion | Thiopurines/methotrexate: 84 [66] | 1 (at least)                          | Completely symptom free                | 13.3n g 40.0n                                                                              |
| Chauvin et al. | Single-center, retrospective study/France| 53                 | 35/57     | 32b,c                    | 26.7b [7.8–75.4]                               | 5 mg/kg IV induction [W 0, 2, and 6] and followed by scheduled infusion every 8 W | Thiopurines/methotrexate: 53 [100] | 3.9n                                  | Steroid-free remission                | ...                                                                                           |
| Dai et al.     | Single-center, prospective study/China | 38                 | 89/127    | CD: 26ac                  | 4 [IQR: 3–8]                                    | ...                                                   |                               | 1c, e                                 | CD: CDAI < 150 UC: Mayo score < 2        | ...                                                                                           |
| Farkas et al.  | Multicenter, prospective study/Hungary | 18                 | 8/10      | 39.9b                    | 6.6 [IQR: 4.0–10.8]                             | 5 mg/kg IV induction [97%], 7.5 mg/kg [1%], or 10 mg/kg [2%] | Thiopurines/ methotrexate: 52 [100] | 2.3b                                  | CD: CDAI < 150 UC: Mayo score < 2        | 1.0c g 0.0c                                                                                   |
| Louis et al.   | Multicenter, prospective study/France and Belgium | 52                 | 26/26     | 32 [26–39]               | 5 mg/kg IV induction [W 0, 2, and 6]                    | ...                                                   |                               | 2.1b                                  | No symptoms or clinical findings indicating active disease                                  | ...                                                                                           |
| Steenholt et al. | Single-center, retrospective study/Denmark | 32                 | 45/34     | CD: 25ac                  | CD: 8.0c [IQR: 5.5–22.6] UC: 4.2c [IQR: 3.8–11.0] | 5 mg/kg IV induction [W 0, 2, and 6]               |                               | CD: 1.4c [IQR: 0.5–3.1] UC: 2.4c [IQR: 0.7–3.2] | No symptoms or clinical findings indicating active disease | ...                                                                                           |
| Laharie et al. | Single-center, retrospective study/France | 61                 | 19/42     | 33 [17–80]               | 5 mg/kg IV induction [W 0, 2, and 6]               | Thiopurines/methotrexate: 59 [98]                 | 2.1                          | CD: 1.4c [IQR: 0.5–7.11]              | ...                                                                                           |
| Rodrigo et al. | Single-center, prospective study/Span | 13                 | 44/37     | 36c [mean, 18–72]        | 5 mg/kg IV induction [W 0, 2, and 6]               | ...                                                   |                               | 1.4 [maximum]                          | Closure of all fistulas                 | ...                                                                                           |

CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; IBD, inflammatory bowel disease; IFX, infliximab; IMM, immunomodulator; IQR, interquartile range; IV, intravenous; n, number of patients; PCDAI, Pediatric Crohn’s Disease Activity Index; pMayo, partial Mayo; SE, standard error; UC, ulcerative colitis; W, weeks. An ellipsis (.) indicates ‘not available’.

*aAge at diagnosis.
*bAge at first IFX infusion.
*cInformation on all study participants is presented because there is no separate information available on patients who underwent IFX retreatment.
*dDuring IFX discontinuation and retreatment.
*eBased on the timepoint after patients had discontinued IFX.
*fBased on the timepoint after patients had been retreated with IFX.
*gWith a cut-off of 3 U/ml.
*hSince the serum infliximab level was >1 mg/l, 73% of the samples were inconclusive.
with UC (78%; 95% CI, 61–91%; $I^2 = 46%$; $\tau^2 = 0.0137$, $p = 0.13$), but the difference was not statistically significant (Figure 3). The numbers of patients with CD and UC were 272 and 48, respectively.

When the results were stratified by studies wherein patients restarted infliximab after a minimum drug holiday of $\geq 16$ weeks, the remission induction rate for patients with IBD was 84% (95% CI, 78–89%; $I^2 = 0%$; $\tau^2 = 0$, $p = 0.57$) as reported in two studies. The results of meta-regression showed that remission induction rates in patients with IBD did not significantly differ according to the proportion of concomitant immunomodulators (Supplementary Figure 1). Moreover, when the results were stratified by study design in the sensitivity analysis, the remission induction rates for patients with IBD, CD, and UC were similar between prospective and retrospective studies (Supplementary Table 3).

The effects of infliximab level on the clinical remission rate were reported only in the study by Baert et al., in which trough levels of infliximab greater than 2 mg/ml were associated with higher remission rates. Biochemical or endoscopic examinations were performed in combination with the assessment of clinical remission in the three studies. However, examinations were conducted for only some participating patients, and biochemical or endoscopic remission rates were not reported.

**Infusion-related reactions**

Seven studies involving 368 patients with IBD were included to evaluate the proportion of patients who experienced infusion-related reactions after infliximab retreatment. Infusion-related reactions were observed in 9% of patients with IBD (95% CI, 3–16%; $I^2 = 77%$; $\tau^2 = 0.0173$, $p < 0.01$; Figure 4). The results of meta-regression showed that the incidence rates of infusion-related reactions in patients with IBD did not significantly differ according to the proportion of concomitant immunomodulators (Supplementary Figure 1). In addition, when the results were stratified by study design, the incidence rates of infusion-related reactions in patients with IBD were similar.
The incidence of severe infusion-related reactions, which were defined as reactions necessitating discontinuation of the infusion owing to significant dyspnea or hypotension was reported in five studies as follows: 0% in three studies and 4% (1/32) and 12.5% (16/128) in two studies, respectively. Most infusion-related reactions were acute and resolved with discontinuation of infliximab infusion, intravenous antihistamines, and steroids. The incidence of hospitalization related to infusion-related reactions has not yet been reported.
Risk of bias
The overall risk of bias of the included studies ranged from 10 to 12, indicating moderate quality (Table 2). All included studies showed a low risk of bias in the following domains: clearly stated aim, inclusion of consecutive patients, follow-up period appropriate to study aim, and <5% lost to follow-up. However, the risks of bias were assessed as high in the unbiased assessment of study endpoints and prospective calculation of study size.

Discussion
This meta-analysis evaluated the efficacy and tolerability of infliximab retreatment for the induction and maintenance of remission in patients with IBD. There is an urgent need for more data to establish standard practice guidelines for clinical remission following infliximab retreatment, as the available data are insufficient. A previous meta-analysis by Gisbert et al.30 found that clinical response to retreatment with the same TNF-α inhibitors was favorable. Compared to their review, our data, including results from five additional studies, demonstrated an acceptable rate of infusion-related reactions as well as favorable rates of the induction and maintenance of remission after infliximab reinduction in patients with IBD. This study suggests that retreatment with infliximab could be a viable alternative to other TNF-α inhibitors for achieving clinical remission in patients with IBD who relapse after discontinuation.

Retreatment with infliximab has been limited in clinical practice owing to concerns, such as the occurrence of severe systemic reactions and reduction of efficacy.12,13,31 In a prospective clinical study, 21% of patients with CD experienced severe systemic reactions following infliximab retreatment.12 In addition, antibodies against infliximab have been detected in 7–30% of patients following retreatment with infliximab.32 According to the US Food and Drug Administration labeling information, an increased incidence of antibodies against infliximab was detected in patients with CD after infliximab reinfusion following a drug holiday of >16 weeks.33 In addition, patients who tested positive for antibodies are likely to experience a lower benefit owing to a faster clearance and lower concentration of the drug than those who are antibody-negative to infliximab.13,31,33 Therefore, the risk of infusion-related reactions and reduced efficacy in patients treated with infliximab have been predicted to be associated with the formation of neutralizing antibodies and degradation of therapeutic antibodies.13,31,34

Contrary to the concern that infliximab retreatment may be associated with unfavorable remission rates owing to drug-induced immunogenicity, this study revealed relatively favorable remission induction rates after infliximab retreatment. The induction of remission after 3 months of infliximab retreatment was achieved in 87% of patients with IBD, which is consistent with a previous meta-analysis demonstrating remission induction in 88% of patients after the reintroduction of discontinued TNF-α inhibitors.9 However, in that study, two TNF-α inhibitors, infliximab or adalimumab, were administered to the patients; therefore, the results cannot be extrapolated to infliximab alone. Moreover, remission rates did not differentiate between induction and maintenance therapies in that study.9

In this study, a higher remission induction rate following infliximab retreatment was observed in patients with CD (88%) than in those with UC (81%), although this finding was not statistically significant. Similar findings have been reported in previous meta-analyses evaluating clinical remission in patients with IBD receiving TNF-α inhibitors including infliximab and adalimumab.9,30 However, the results of this study should be interpreted with caution, as the number of patients with UC was small and the 95% CIs overlapped.

According to the pooled rate from two studies involving a small sample size of 154 patients in our meta-analysis results, the number of patients who maintained remission in patients responsive to infliximab induction therapy was decreased. Although only a few studies have focused on maintaining the induction of remission in infliximab retreatment, this tendency of decreasing rate of remission maintenance over time is consistent with the findings of previous randomized controlled trials.8,35

The remission induction and maintenance rates of this study should be interpreted considering the concomitant use of immunomodulators. Although a subanalysis in this study did not show the combined effect of immunomodulators, several studies have shown that concomitant treatment with immunomodulators increases the clinical remission rate of infliximab treatment.35–37
Table 2. Individual MINORS scores.

| Study            | Clearly stated aim | Inclusion of consecutive patients | Prospective data collection | Endpoints appropriate to study aim | Unbiased assessment of study endpoint | Follow-up period appropriate to study aim | <5% lost to follow-up | Prospective calculation of study size | Total |
|------------------|--------------------|-----------------------------------|-----------------------------|------------------------------------|---------------------------------------|------------------------------------------|-----------------------|----------------------------------------|-------|
| Kang et al.       | 2                  | 2                                 | 1                           | 0                                  | 2                                     | 2                                        | 0                     |                                        | 10    |
| Baert et al.      | 2                  | 2                                 | 1                           | 2                                  | 2                                     | 2                                        | 0                     |                                        | 12    |
| Chauvin et al.    | 2                  | 2                                 | 1                           | 2                                  | 2                                     | 2                                        | 0                     |                                        | 11    |
| Dai et al.        | 2                  | 2                                 | 2                           | 2                                  | 0                                     | 2                                        | 2                     |                                        | 12    |
| Farkas et al.     | 2                  | 2                                 | 2                           | 2                                  | 0                                     | 2                                        | 2                     |                                        | 12    |
| Louis et al.      | 2                  | 2                                 | 2                           | 1                                  | 0                                     | 2                                        | 1                     |                                        | 12    |
| Steenholdt et al. | 2                  | 2                                 | 1                           | 2                                  | 1                                     | 2                                        | 2                     |                                        | 12    |
| Laharie et al.    | 2                  | 2                                 | 1                           | 2                                  | 0                                     | 2                                        | 2                     |                                        | 11    |
| Rodrigo et al.    | 2                  | 2                                 | 2                           | 2                                  | 0                                     | 2                                        | 2                     |                                        | 12    |

Note: Additional criteria (unbiased assessment of study endpoint, adequate control group, contemporary groups, baseline equivalence of groups, and adequate statistical analyses) were not included since all studies were single-arm studies.
This study suggests that infliximab retreatment was well tolerated with a comparable rate of infusion-related reactions with that reported in previous studies. The pooled rate of infusion-related reactions following infliximab retreatment was approximately 9%, similar to that reported in previous studies, ranging from 2% to 27%.38–41 However, immunomodulators were concomitantly used with infliximab in most studies included in our meta-analyses. Accordingly, the effect on immunomodulators should be considered when interpreting the efficacy and safety of infliximab retreatment. The effectiveness and safety of combination therapy with biologic and immunomodulators have been evaluated in several studies.35,36,42

As the therapeutic strategies for IBD have changed, the importance of biologics used in IBD patients has substantially increased. Meanwhile, the concerns on the risk of immunogenicity of biologics associated with nonremission and loss of disease control have been raised, the concomitant use of immunomodulators has been suggested as a treatment option for reducing the risk of immunogenicity.13,44 Several studies have shown that the concomitant use of immunomodulators has a protective effect against anti-infliximab antibody formation and reduces the incidence of infusion-related reactions.35,36,42 Notably, continuing the use of immunomodulators during drug holidays was reported to be associated with reduced immunogenicity when biologics were reintroduced.44 Because four studies that did not provide detailed information on the concomitant use of immunomodulators during the drug holidays and retreatment period were not included in our meta-regression analysis, the exact effectiveness and safety of infliximab retreatment, excluding the effect of immunomodulators, cannot be determined from our results. Therefore, further studies comparing the effect of immunomodulator use at different time periods in infliximab retreatment are needed.

This study had several limitations. First, this meta-analysis included single-arm studies, wherein it is difficult to demonstrate the efficacy of a treatment in the absence of a comparison group and assess the practical benefits of clinically relevant endpoints. Second, the included studies were heterogeneous in terms of follow-up duration, drug holiday duration, and definition of clinical remission, which may have affected the results of this meta-analysis. Third, subanalyses based on the proportion of patients who tested positive for antibodies against infliximab and serum concentration of infliximab could not be performed owing to the sparsity of data. Fourth, endoscopic remission is an important endpoint in determining the efficacy of IBD treatment. In this study, we were unable to assess mucosal healing or endoscopic remission because most of the included studies lacked endoscopic measurements after infliximab retreatment. Furthermore, the overall risk of bias for the included studies was moderate, and the risk of bias in the unbiased assessment of the study endpoint and prospective calculation of the study size was high.

Infliximab retreatment resulted in favorable remission induction and maintenance rates with tolerable infusion-related reactions in patients with IBD who achieved remission with initial infliximab treatment but relapsed its discontinuation. Thus, infliximab can be considered a potential retreatment option in patients with IBD who previously responded well to infliximab treatment. Further studies evaluating the long-term outcomes of infliximab retreatment are needed to compare its effects with those of conventional therapies in patients with IBD.

Author contribution
Y.M.Y. and J.H.C. conceptualized and designed the study and prepared the manuscript. S.Y. (Seungwon Y.) performed the data analysis and drafted the manuscript. S.Y. (Siyoung Y.) conducted a literature search and performed data extraction and analysis. Y.K.J. conducted a literature search and performed the data extraction. S.K. performed the data analysis, interpreted the data, and revised the manuscript. M.J.C. and J.C. interpreted the data and reviewed the manuscript. All authors reviewed, amended, and approved the manuscript for submission.

Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.Y. has been employed by Celltrion, a biopharmaceutical company that produces infliximab. The other authors declare no conflicts of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Supplemental material
Supplemental material for this article is available online.

References
1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12: S3–S9.
2. Danese S and Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713–1725.
3. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113: 481–517.
4. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114: 384–413.
5. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443–1453.
6. Levin AD, Wildenberg ME and van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 2016; 10: 989–997.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (London, England) 2002; 359: 1541–1549.
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
9. Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther 2016; 43: 910–923.
10. Doherty G, Katsanos KH, Burisch J, et al. European Crohn’s and Colitis Organisation topical review on treatment withdrawal ["exit strategies"] in inflammatory bowel disease. J Crohns Colitis 2018; 12: 17–31.
11. Casanova MJ, Chaparro M, Garcia-Sanchez V, et al. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study. Am J Gastroenterol 2017; 112: 120–131.
12. Kugathasan S, Levy MB, Saian K, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408–1414.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601–608.
14. Kang B, Choi SY, Choi YO, et al. Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn’s disease patients treated with combined immunosuppressive therapy. J Crohn’s Colitis 2018; 12: 644–652.
15. Chauvin A, Le Thuaut A, Belhassan M, et al. Infliximab as a bridge to remission maintained by antimitabolite therapy in Crohn’s disease: a retrospective study. Dig Liver Dis 2014; 46: 695–700.
16. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
17. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017; 11: 3–25.
18. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73: 712–716.
19. Khan W, Khan M, Alradwan H, et al. Utility of intra-articular hip injections for femoroacetabular impingement: a systematic review. Orthop J Sports Med 2015; 3: 2325967115601030.
20. Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
21. Higgins JP and Thomas J. Cochrane handbook for systematic reviews of interventions, 2019, version 6, http://www.handbook.cochrane.org
22. Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods 2019; 10: 83–98.
23. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12: 1474–1478.

24. Farkas K, Lakatos PL, Nagy F, et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013; 48: 1394–1398.

25. Laharie D, Chanteloup E, Chabrun E, et al. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders. Aliment Pharmacol Ther 2009; 29: 1240–1248.

26. Louis E, Mary JY, Verniermassouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63–70.

27. Rodrigo L, Pérez-Pariente JM, Fuentes D, et al. Retreatment and maintenance therapy with infliximab in fistulizing Crohn’s disease. Rev Esp Enferm Dig 2004; 96: 548–554; 554–548.

28. Steenholdt C, Molazahi A, Ainsworth MA, et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518–527.

29. Dai C, Liu WX, Jang M, et al. Mucosal healing did not predict sustained clinical remission in patients with IBDD after discontinuation of one-year infliximab therapy. PLoS ONE 2014; 9: e110797.

30. Gisbert JP, Marin AC and Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2016; 111: 632–647.

31. Ben-Horin S and Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33: 987–995.

32. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepato 2004; 2: 542–553.

33. Drug approval package, REMICADE® (infliximab) lyophilized concentrate for injection, Approval, 1998, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf (accessed 1 December 2020).

34. Brandse JF, Peters CP, Geeske KB, et al. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn’s disease. Inflamm Bowel Dis 2014; 20: 251–258.

35. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876–885.

36. Colombel JF, Sandborn WJ, Reimisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383–1395.

37. Faleck DM, Shmidt E, Huang R, et al. Effect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn’s disease: a systematic review and pooled meta-analysis. Clin Gastroenterol Hepato 2021; 19: 238–245.

38. Ebada MA, Elmatboly AM, Ali AS, et al. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Int J Colorectal Dis 2019; 34: 1633–1652.

39. Saman S, Goetz M, Wendler J, et al. Ustekinumab is effective in biological refractory Crohn’s disease patients—regardless of approval study selection criteria. Intest Res 2019; 17: 340–348.

40. Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther 2020; 52: 1341–1352.

41. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829–838.

42. O’Meara S, Nanda KS and Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 1–6.

43. Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis 2019; 25: 1417–1427.

44. Chapman TP, Gomes CF, Louis E, et al. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2020; 5: 63–79.